Oryon Cell Therapies Raises $21 Million in Series A Funding
Oryon Cell Therapies, a Belmont, Massachusetts-based company specializing in cell therapy technologies, has successfully closed a $21 million Series A funding round. The investment was supported by Neuro.VC and Byers Capital.
Company Overview
Founded by Nikola Kojic, MD-PhD, and Ole Isacson, with Ron Cohen, M.D. serving as CEO, Oryon Cell Therapies focuses on advancing innovative treatments in the field of regenerative medicine. The company aims to develop therapies that can potentially address a range of medical conditions through the use of cellular technology.
Investors and Funding Details
The Series A funding round did not have a designated lead investor but attracted significant interest from notable investors Neuro.VC and Byers Capital. This infusion of capital is expected to propel Oryon Cell Therapies' research and development efforts, enhancing their capacity to bring new therapies to market.
Planned Utilization of Funds
While specific details on the allocation of the newly acquired funds were not disclosed, such investments typically aim to expand research capabilities, accelerate clinical trials, and potentially scale up production facilities. These steps are crucial for advancing the company's therapeutic pipeline and moving closer to regulatory approvals.
Leadership Insights
CEO Ron Cohen, M.D., expressed the team’s dedication to leveraging this funding to drive forward their mission of developing groundbreaking cell therapies. "We are thrilled to have the support of investors who share our vision for the future of regenerative medicine," Cohen noted.
Conclusion
The successful securing of $21 million in Series A funding marks a significant milestone for Oryon Cell Therapies. With the backing of Neuro.VC and Byers Capital, the company is well-positioned to continue its pioneering work in cell therapy, potentially offering new hope for patients with unmet medical needs.